Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

We recently published a list of 12 Best Quality Stocks to Invest in Now. In this article, we are going to take a look at ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

Like many pharma stocks, Eli Lilly (NYSE: LLY ... loss candidate it's suggested may be even more effective than its current drugs, and orforglipron, a weight loss candidate in pill form.

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Seeking more efficient drug development, pharmaceutical giants and startups are encouraging AI fluency and in some cases ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...